The national collection lost the election of well-known pharmaceutical companies responded.

According to Minetrain data, metformin oral normal release agent type (0.25g, 0.5g) has 30 enterprises, metformin slow release control agent type (0.5g) has 17 enterprises.
however, according to the requirements of the procurement documents, each product rules of up to 8 selected, the difficulty of the selection and the degree of competition is obviously greater than other varieties, "group of death" self-evident.
the results of the proposed election, the current round of metformin quotation situation is simply a big surprise, some enterprises reported insufficient effective declared price 1/10 of the price bidding.
such as metformin hydrochloride tablets, as low as 1.5 cents per tablet, and diphthalate tablets, as low as 6.8 cents per tablet.
metformin, has entered the era of "score-based".
the third batch of national collection of metformin in the proposed selection situation: the election, only to live in the national collection, we often hear a sentence - "barefoot is not afraid to wear shoes."
means a small business product, or a product that has just been approved for no market share, to open up the market through a low-cost strategy.
There are pharmaceutical companies to Cypress Blue revealed that in yesterday's quotation process we are almost all running to the floor price to go, metformin oral regular release dosage form two specifications, many pharmaceutical companies are basically at a loss, and heard that there are enterprises reported low prices are actually the wrong price.
from the major industry media coverage of the situation on the scene, we can feel that tension.
the above-mentioned pharmaceutical companies said that metformin has a large number of enterprises, there are large-scale, rich product lines of well-known enterprises, but also small-scale, single-product small enterprises.
this case, for small businesses, it's the barefoot one.
, after all, for this product through the consistent evaluation of desperate, cost the enterprise to bear the scope of huge costs.
Just after the evaluation met the national collection, I do not know whether it is lucky or unlucky, but in any case, it is not easy to get the national collection of tickets, in order for enterprises can continue to live, only the first bid to say.
According to MIMI data, the market size of metformin in 2019 reached 5.47 billion yuan, in the face of huge demand, the market has maintained a high growth trend in recent years, although the growth rate in 2019 slightly lower than in 2018, but the growth rate is still as high as 19.22%.
(Source: Minernet) The huge market is attracting many pharmaceutical companies who want a piece of the pie.
there is no doubt that with metformin into the national harvest, the market pattern of metformin will be reconstructed once again, the enterprises that have not been selected will also face greater competitive pressure.
if you don't choose a variety? There is one product worth mentioning about where to go after the unseeded election.
Baiyang Pharmaceutical's hydrochloric metformin slow release tablets (III.), is the first Sino-US osmotic pump-controlled release agent type metformin, approved for listing in China at the beginning of this year.
China Pharmaceutical Business Association vice president, Baiyang Pharmaceutical Group Chairman Fu Gang said to Cypress Blue, Baiyang metformin belongs to three new types of drugs, and other generic drugs are not in the same category, its use of advanced penetration pump control and release technology.
I.) (II.) (III)), the technical difficulty is not the same, if mixed together to bid, for drugs like high cost, high added value, dosage form advantage is really difficult.
fugang believes that for metformin, there are still good opportunities for development in the retail channels.
As far as Baiyang is concerned, in addition to responding to the national call, it will also make use of Baiyang's strong pharmacy marketing network, as well as the service capacity of consumers and patients, so that penetration pump metformin through online and retail channels to better develop the market.
he said that there are many other enterprises' products, in fact, there is such a need, should also grasp such market opportunities.
Previously, some experts have said to Cypress Blue, through the consistent evaluation of generic drugs and the original drug competition, if the bidding is too fierce, the price reduction is too large, the original research drug manufacturers have the possibility to withdraw from the volume of procurement.
from the current round of national collection, for most of the original pharmaceutical companies, have opted out.
such as Sidnafa, metformin, the original pharmaceutical companies have abandoned the bid.
to this, Fu Gang said, for the original research brand drugs, due to the use of drug habits and consumption levels of differences, many people on the original research drug demand is still.
some of the original research drugs have formed a certain scale, the future of its brand premium in retail is still there.
believes that the impact of mining on the circulation of the industry may be more serious than the general public think, because the price of drugs fell particularly large, will lead to a number of original research drugs out of the hospital market.
point of view, the hospital's function as the main channel for the sale of prescription drugs is also rapidly weakening, and the transfer of the main channel of drug sales from the hospital to the professional pharmacy is a huge channel change.
, actively explore the market outside the collection, such as retail terminals, Internet sales channels, etc., will become the collection of unseeded varieties of the next key layout direction.
.